Preserving mitochondrial pools of nicotinamide adenine dinucleotide (NAD) or nicotinamide phosphoribosyltransferase (Nampt), an enzyme involved in NAD production, maintains mitochondrial function and confers neuroprotection after ischemic stress. However, the mechanisms involved in regulating mitochondrial-localized Nampt or NAD have not been defined. In this study, we investigated the roles of protein kinase C epsilon (PKCe) and AMP-activated protein kinase (AMPK) in regulating mitochondrial pools of Nampt and NAD after resveratrol or ischemic preconditioning (IPC) in the cortex and in primary neuronal-glial cortical cultures. Using the specific PKCe agonist ceRACK, we found that PKCe induced robust activation of AMPK in vitro and in vivo and that AMPK was required for PKCe-mediated ischemic neuroprotection. In purified mitochondrial fractions, PKCe enhanced Nampt levels in an AMPK-dependent manner and was required for increased mitochondrial Nampt after IPC or resveratrol treatment. Analysis of intrinsic NAD autofluorescence using two-photon microscopy revealed that PKCe modulated NAD in the mitochondrial fraction. Further assessments of mitochondrial NAD concentrations showed that PKCe has a key role in regulating the mitochondrial NAD þ / nicotinamide adenine dinucleotide reduced (NADH) ratio after IPC and resveratrol treatment in an AMPK-and Nampt-dependent manner. These findings indicate that PKCe is critical to increase or maintain mitochondrial Nampt and NAD after pathways of ischemic neuroprotection in the brain.
INTRODUCTION
Nicotinamide adenine dinucleotide (NAD) is an essential coenzyme used by the tricarboxylic acid cycle and electron transport chain in the maintenance of mitochondrial membrane potential and production of ATP. 1 In the brain, reductions in NAD after oxidative stress or ischemic events cause mitochondrial depolarization, decreased respiration, apoptotic signaling, and neuronal death. [2] [3] [4] Conversely, increases in cellular NAD have been shown to prevent mitochondrial dysfunction and neurodegeneration after cerebral ischemia. 5, 6 Ischemic preconditioning (IPC), a paradigm where a brief ischemic insult protects the brain against a subsequent lethal ischemic injury, or treatment with the polyphenol resveratrol, has been shown to protect mitochondria and enhance levels of NAD in the brain. [7] [8] [9] [10] The mechanism by which resveratrol and IPC regulate NAD levels has not been clearly defined. However, two key signaling pathways that may be involved are protein kinase C epsilon (PKCe) and AMP-activated protein kinase (AMPK), enzymes that regulate mitochondrial ischemic neuroprotection after IPC and resveratrol treatment. 9, 11 Protein kinase C epsilon activity has been associated with increased expression of aspartate amino transferase and malate dehydrogenase, two major components of the malateaspartate shuttle. 12 This redox shuttle is responsible for maintaining electron transfer between cytoplasmic and mitochondrial pools of NAD. 13 AMP-activated protein kinase enhances whole-cell levels of NAD by increasing the expression of nicotinamide phosphoribosyltransferase (Nampt), the rate-limiting enzyme in the major biosynthetic pathway for NAD production. 14 Nicotinamide phosphoribosyltransferase overexpression has been shown to maintain mitochondrial function and protect the brain against ischemic injury through its ability to produce NAD. 6, 15 The mitochondrial NAD pool is distinct and is regulated separately from the rest of the cell. [16] [17] [18] [19] In the brain, the mitochondria contain a large portion of the total cellular NAD, 16 indicating the importance of mitochondrial pools of NAD to neuronal and astrocyte function. In neurons, enhancements in mitochondrial NAD after oxidative stress preserved mitochondrial membrane potential, enhanced respiration, and prevented the release of apoptosis-inducing factor. 18 Similarly, increased mitochondrial NAD content protected the heart from damage after postischemic reperfusion. 17 Maintenance of mitochondriallocalized Nampt was shown to enhance mitochondrial NAD and preserve liver cell viability after genotoxic-induced exhaustion of cytoplasmic NAD. 19 Collectively, this evidence indicates an important role for mitochondrial-specific Nampt and NAD in promoting mitochondrial function and cytoprotection against lethal stress. However, the mechanisms regulating mitochondrial pools of NAD are not well defined.
The goal of the present study was to determine whether PKCe and AMPK work together to regulate mitochondrial pools of Nampt and NAD after preconditioning paradigms in the cortex. AMP-activated protein kinase has previously been linked to the PKC family in IPC-mediated cardioprotection in the heart, 20 but no specific PKC isoform has been identified. Therefore, we first hypothesized that PKCe regulates AMPK activity in the brain. We next investigated whether PKCe and AMPK are involved in modulating mitochondrial-localized Nampt. Finally, since previous studies showed that IPC and resveratrol regulate mitochondrial NAD 7, 8 and that PKCe is involved in improving mitochondrial function, 9 we tested the hypothesis that PKCe enhances mitochondrial pools of Nampt and NAD after IPC or treatment with resveratrol.
MATERIALS AND METHODS
All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and approved by the Animal Care and Use Committee of the University of Miami.
Mixed Cortical Neuron/Astrocyte Cell Cultures
Neuronal-glial cocultures were prepared from Sprague-Dawley rats as previously described. 21 For glial astrocytes, 1-to 2-day-old pups were anesthetized by intraperitoneal injection of ketamine (1.0 mg/pup), killed, and the brains were quickly removed. The cerebral cortices of the pups were isolated and the dissociated astrocytes were plated at 1.5 cortical hemispheres/24-well plate with MEM (minimum essential medium) (Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum, 10% equine serum, 2 mmol/L glutamine, and 1% penicillin-streptomycin. After 2 weeks, 18-to 19-day pregnant Sprague-Dawley rats were anesthetized by isoflurane and embryos were quickly removed and decapitated. The cerebral cortices of the embryos were isolated and the dissociated cortical neurons were plated in MEM containing 5% fetal bovine serum and 2 mmol/L glutamine on the confluent monolayer of astrocytes prepared 2 weeks previously. Every 3 to 4 days, half of the media was changed with normal maintenance media consisting of MEM containing 2 mmol/L glutamine. The mixed cortical neuron/astrocyte cultures were kept in an incubator containing 5% CO 2 at 371C and used after 2 weeks in vitro.
Induction of Oxygen-Glucose Deprivation
To mimic ischemia, we subjected cultures to oxygen-glucose deprivation (OGD 
Pharmacological Treatments
For in vivo experiments, 3-month-old male Sprague-Dawley rats underwent intraperitoneal injection with 0.5 mg/kg of Tat-conjugated ceRACK (PKCe agonist) or the Tat peptide (KAI Pharmaceuticals, San Francisco, CA, USA). Cortices were collected for analysis 1 hour or 48 hours after injection. For in vitro experiments, cultures were exposed for 1 hour to 25 mmol/L resveratrol (Sigma), 100 nmol/L of Tat-conjugated ceRACK, or 0.5 mmol/L AICAR (AMPK activator) (Sigma) with or without 15 mmol/L Compound C (CC) (AMPK inhibitor) (EMD Millipore, Billerica, MA, USA) or 100 or 250 nmol/L of Tat-conjugated eV1-2 (PKCe antagonist) (KAI Pharmaceuticals). Cultures were used for experimental analyses 30 minutes or 48 hours after pharmacological preconditioning treatment.
Assessment of Neuronal Death
Forty-eight hours after pharmacological treatment, cultures were subjected to 4 hours of OGD (lethal OGD), after which the media was replaced with normal maintenance media and placed back into the incubator. To determine neuronal death, cytotoxicity was measured by lactate dehydrogenase (LDH) released for 48 hours into culture medium after lethal OGD using a Cytotoxicity Detection Kit (Roche Diagnostics Corporation, Indianapolis, IN, USA). Maximal neuronal LDH release was measured in the neuron-glial cocultures exposed to N-methyl-D-aspartate (500 mmol/L), an excitotoxin that preferentially kills neurons, for 48 hours. Lactate dehydrogenase release was measured at an absorbance of 340 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Values were expressed relative to LDH measurement from maximal neuronal LDH.
Isolation of Mitochondrial Fractions
Cortices or cultures were washed twice in cold (41C) isolation medium consisting of (in mmol/L) 225 mannitol, 75 sucrose, 5 HEPES, and 1 EGTA, pH 7.4 and then homogenized in a hand-operated glass Teflon homogenizer in isolation medium. The homogenates were centrifuged at 1,300 Â g for 5 minutes. The resulting supernatant was centrifuged at 17,000 Â g for 10 minutes and the supernatant pellet was used as the source of the crude mitochondrial fraction. This pellet was resuspended in 15% Percoll and layered over a preformed gradient of 22% Percoll which was layered over 50% Percoll. The Percoll density gradient was centrifuged at 17,000 Â g for 10 minutes and the purified mitochondria were collected at the interface between 50% and 22% gradients. 22 The purified mitochondrial sample was centrifuged at 7,000 Â g for 10 minutes and the final pellet resuspended in isolation medium without EGTA.
Western Blot Analysis
Cells or mitochondria were lysed in RIPA buffer pH 8.0 containing 150 mmol/L NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mmol/L Tris, supplemented with 1% protease and 1% phosphatase inhibitor cocktails (Sigma) and then centrifuged at 15,900 g for 15 minutes. Equal amounts of proteins were subjected to 8%, 10%, or 12% SDS-polyacrylamide gel electrophoresis and the separated proteins were electrophoretically transferred onto PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). The blot was blocked with 5% nonfat dried milk, incubated overnight at 41C with phospho-AMPKa (Thr172) (1:250), AMPKa (1:1,000), phospho-acetyl-CoA carboxylase (Ser79) (1:500), acetyl-CoA carboxylase (1:1,000), CoxIV (1:1,000), b-actin (1:2,000) (Cell Signaling Technology, Danvers, MA, USA), or Nampt (1:125) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies. Then, incubation was followed by horseradish peroxidase-conjugated specific secondary antibody for 1 hour at room temperature. The immunoreactive bands were revealed by ECL western blotting detection reagents (Pierce Thermo Scientific, Rockford, IL, USA). Western blot images were digitized by means of a CCD camera equipped with 50 mm NIKKOR lens (Nikon, Tokyo, Japan). The camera was interfaced to the Versadoc Imaging System (Bio-Rad). The digitized immunoblots were subjected to densitometric analysis using the Quantity One 1-D Analysis software (Bio-Rad).
Immunohistochemistry
Rats were perfused under anesthesia with fixative comprised of 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4. Brains were removed and incubated in fixative overnight before being suspended in sucrose for 24 hours. Brains were quickly frozen on dry ice and 30-mm-thick sections were cut using a cryostat. The cortical sections were washed in PBS and then blocked in 5% goat serum albumin in PBS-T (0.8% Triton X-100 in PBS) overnight at 41C. The sections were then incubated with CoxIV mouse antibody (1:50; Cell Signaling Technology) and Nampt rabbit antibody (1:150; Bethyl Laboratories, Montgomery, TX, USA) in 1% BSA in PBS-T at 41C for 72 hours. After washing with PBS, cortical sections were incubated with anti-mouse Alexa Fluor 568 (1:500; Abcam, Cambridge, MA, USA) and anti-rabbit Hilytefluor 488 (1:500; AnaSpec, Fremont, CA, USA) for 2 hours in the dark at room temperature. The nuclei were stained with Hoechst 33342 (Life Technologies) for 10 minutes and then the sections were washed several times with PBS. The cortical sections were mounted on slides using the Prolong Antifade reagent (Molecular Probes, Carlsbad, CA, USA) and were visualized using confocal microscopy at Â 150 magnification. Images were acquired with the FLUOVIEW FV1000 imaging system (Olympus, Center Valley, PA, USA) and then the Image J software (National Institute of Health, Bethesda, MD, USA) was used to quantify fluorescence. Colocalization of fluorescence was assessed using the colocalization._class plugin for Image J which defined areas of colocalization with white pixilation.
Two-Photon Imaging of Intrinsic Mitochondrial Nicotinamide Adenine Dinucleotide Reduced Fluorescence
Neuron-glial cocultures were grown onto glass coverslips in 24-well plates and cultured in vitro for 2 weeks as described above. Forty-eight hours after preconditioning, cultures were exposed to 250 nmol/L Mitotracker Red CMX Ros (Life Technologies) to label mitochondria. Coverslips were then placed into a petri dish containing normal maintenance media. Nicotinamide adenine dinucleotide exists in both an oxidized (NAD þ ) and reduced (NADH) form. Two-photon microscopy controlled by the Lasersharp 2000 software (Bio-Rad) was used to excite intrinsic mitochondrial NADH fluorescence at 740 nm. 23, 24 Emission spectra of the twophoton excited intrinsic tissue fluorescence were obtained by scanning a region using a Â 10 objective (Olympus NA 0.40 UPLASAPO) at a resolution of 1,280 Â 1,024. Maximal intrinsic mitochondrial NADH fluorescence was measured 2 minutes after exposure to 1 mmol/L potassium cyanide (KCN), a potent reducing agent.
Measurement of Mitochondrial Nicotinamide Adenine Dinucleotide
Total NAD þ and NADH levels in purified mitochondrial samples were quantified using a NAD þ /NADH quantification kit according to the manufacturer's instructions (Biovision, Milpitas, CA, USA). Total NAD þ /NADH levels were assessed by converting all NAD þ in the samples to NADH using the NAD Cycling Enzyme Mix and NADH Developer included in the kit. Nicotinamide adenine dinucleotide reduced-only concentrations were achieved by heating the mitochondrial samples to 601C for 30 minutes to decompose all NAD þ . Nicotinamide adenine dinucleotide reduced was measured at OD 450 nm using a spectrophotometer microplate reader (BioTek Instruments, Winooski, VT, USA). Known concentrations of purified NADH were used to generate standard curves and to calculate mitochondrial concentration. Values of NAD þ were generated by subtracting the NADH-only value from the total NAD þ /NADH value.
Statistical Analysis
All data were expressed as the mean ± s.e.m. Statistical significance was determined with Student's t-test for comparison between two groups or one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test for comparison between more than two groups. In all cases, a P value of o0.05 was considered as statistically significant.
RESULTS

Protein Kinase C epsilon Is a Major Regulator of AMP-Activated Protein Kinase Activity
Previous studies in the heart have linked an AMPK-PKC pathway to ischemic protection, 20 but the involvement of a specific PKC isoform has not been determined. Since both PKCe and AMPK protect mitochondria, we hypothesized that PKCe and AMPK functionally cooperate to provide ischemic protection in the brain. To test this, we first assessed neuronal death induced by 4 hours of OGD in neuronal-glial cortical cultures. One-hour pretreatment with the Tat-conjugated PKCe activator (ceRACK; 100 nmol/L) resulted in 45.8 ± 1.5% neuronal death, which was significantly lower than the Tat-only treatment (74.6 ± 1.2%; Po0.001, n ¼ 6) ( Figure 1A ). However, this neuroprotection was reversed with the addition of the AMPK inhibitor CC (15 mmol/L), indicating that AMPK functions as a downstream target of the PKCe pathway.
To determine whether PKCe regulates AMPK activity, we analyzed whole-cell lysates in neuronal-glial cortical cultures 30 minutes after 1 hour of ceRACK (100 nmol/L) exposure, which revealed significant increases in levels of phospho-AMPK Thr172 (by 1.6±0.1fold; Po0.01, n ¼ 5) ( Figure 1B) , the activated form of AMPK. To further confirm AMPK activity, we also assessed the phosphorylation of acetyl-CoA carboxylase (ACC), a direct downstream target of AMPK. ACC Ser79 phosphorylation was also significantly increased after ceRACK treatment (by 1.8±0.2-fold; Po0.05, n ¼ 5) ( Figure 1B ). To determine whether PKCe activates AMPK in vivo, whole-cell lysates were collected from the cortex 1 hour after ceRACK intraperitoneal injection (0.5 mg/kg) which also resulted in significant increases in phospho-AMPK Thr172 (by 1.6 ± 0.1-fold; Po0.05, n ¼ 3), and phospho-ACC Ser79 (by 1.5 ± 0.1fold; Po0.05, n ¼ 3) indicating that PKCe is sufficient to activate AMPK ( Figure 1C ).
Both IPC and resveratrol have been previously shown to enhance AMPK activity. 8, 20 To investigate whether PKCe is the key signaling pathway required for AMPK activation during ischemic or resveratrol preconditioning, we exposed glialneuronal cortical cultures to the Tat-conjugated PKCe inhibitor (eV1-2) at 250 nmol/L during IPC, or 100 nmol/L during resveratrol preconditioning. In previous studies, we have used the PKCe antagonist eV1-2 quite extensively 9,25-27 and treatment with this inhibitor alone showed no effect on neuroprotection or mitochondrial functioning. However, inhibition of PKCe activity during preconditioning treatment blocked increases in AMPK Thr172 and ACC Ser79 phosphorylation 30 minutes after IPC (Po0.05, n ¼ 5) and resveratrol preconditioning (Po0.05, n ¼ 5) ( Figures 1D and 1E ). Collectively, these results showed that PKCe is both sufficient and necessary for the induction of AMPK activity after ischemic and resveratrol preconditioning.
Protein Kinase C epsilon Regulates Mitochondrial Pools of Nampt AMP-activated protein kinase has been previously shown to increase whole-cell levels of Nampt by enhancing Nampt mRNA expression. 14 At this time it is unknown whether AMPK also regulates mitochondrial pools of Nampt, which are regulated separately from the cytoplasmic pools. 19 Since our previous experiments indicated that PKCe and AMPK activity is linked, we next wanted to determine whether the PKCe-AMPK pathway is involved in regulating Nampt levels in mitochondria from neuronal-glial cortical cultures. We first assessed whether PKCe and AMPK require each other for the modulation of Nampt in isolated mitochondria from glial-neuronal cortical cultures. Protein levels of mitochondrial-localized Nampt were increased by 1.4 ± 0.09-fold 48 hours after 100 nmol/L treatment with ceRACK (Po0.01, n ¼ 6). This increase was blocked with addition of CC (15 mmol/L), an AMPK inhibitor. Treatment with AICAR (AMPK activator) (0.5 mmol/L) also enhanced mitochondrial Nampt by 1.5 ± 0.1-fold (Po0.01, n ¼ 6), but these increases were blocked with the addition of the PKCe inhibitor eV1-2 (100 nmol/L) ( Figure 2A) . These results show that there is reciprocal regulation of mitochondrial Nampt between PKCe and AMPK.
We next examined the role of PKCe and AMPK in regulating mitochondrial pools of Nampt after ischemic or resveratrol preconditioning in neuronal-glial cortical cultures. Ischemic preconditioning induced a 1.7 ± 0.2-fold increase in Nampt levels 48 hours later, which was blocked with the addition of the PKCe inhibitor eV1-2 (250 nmol/L) (Po0.01, n ¼ 6). Exposure to the AMPK inhibitor CC (15 mmol/L) during IPC had no effect on mitochondrial Nampt levels ( Figure 2B) . Similarly, addition of eV1-2 (100 nmol/L), but not CC (15 mmol/L), reduced the resveratrolmediated 1.5±0.2-fold increases in mitochondrial Nampt 48 hours later (Po0.01, n ¼ 6) ( Figure 2C ). These results provide evidence that PKCe, but not AMPK, is essential for increased mitochondrial Nampt after ischemic or resveratrol preconditioning.
To determine whether the PKCe regulation of Nampt observed in vitro also occurs in adult cortex in vivo, we used immunohistochemical analysis to assess the nuclear marker Hoechst (blue), Nampt (green), and the mitochondrial marker CoxIV (red) in the cortex 48 hours after intraperitoneal injection of Tat or ceRACK ( Figure 3A) . Overall, Nampt fluorescence was increased by 30 ± 0.1% (Po0.01, n ¼ 3) ( Figure 3B ). Further analysis of Nampt and CoxIV fluorescence revealed a 2.1±0.3-fold increase (Po0.05, n ¼ 3) in colocalization after ceRACK treatment, as indicated by the white areas of pixilation ( Figures 3C and 3D ). Western blotting of isolated mitochondria from the cortex 48 hours after intraperitoneal injection of Tat or ceRACK showed a 1.6±0.1-fold increase in Nampt levels (Po0.05, n ¼ 6) with PKCe activation ( Figure 3E ).
Protein Kinase C epsilon Modulates the Mitochondrial Nicotinamide Adenine Dinucleotide Oxidized to Reduced Ratio
Nicotinamide phosphoribosyltransferase is the rate-limiting enzyme in the major biosynthetic pathway for the production of NAD. 13 Nicotinamide adenine dinucleotide exists in both an oxidized (NAD þ ) and a reduced (NADH) form. It has been reported that increases in Nampt expression increase NAD þ levels and the NAD þ /NADH ratio. 6, 14, 15 Since our previous experiments identified PKCe as a regulator of mitochondrial Nampt, we now wanted to determine whether PKCe has a role in regulating mitochondrial levels of NAD þ , NADH, and the NAD þ /NADH ratio in the cortex.
To assess mitochondrial NADH, we used two-photon microscopy to perform live-cell imaging of NADH autofluorescence in neuronal-glial cortical cultures. Two-minute exposures to KCN, a potent mitochondrial reduction agent, increased NADH fluorescence in a dose-dependent manner ( Figure 4A ). This verified that the observed fluorescence was derived from NADH. Since NADH fluorescence does not include its oxidized form NAD þ , exposure to concentrations above 1 mmol/L KCN maximally reduced mitochondria to reveal total mitochondrial NAD (NAD þ and NADH) ( Figure 4A ). We further confirmed that the observed NADH autofluorescence is primarily of mitochondrial origin 24 by showing colocalization of NADH fluorescence with mitotracker, a live-cell mitochondrial marker ( Figure 4B ). To determine whether PKCe enhances the NAD þ /NADH ratio, we compared basal and maximal NADH fluorescence (induced with 1 mmol/L KCN) 48 hours after 1 hour treatment with Tat or ceRACK (100 nmol/L) ( Figure 4C ). Maximal NADH fluorescence increased by 45 ± 1% in Tat-treated and 70 ± 5% in ceRACK-treated cultures in comparison with baseline NADH fluorescence (Po0.001, n ¼ 6) ( Figure 4D ), indicating that PKCe activation increased the NAD þ /NADH ratio.
Since the previous experiment only allowed for the analysis of NADH fluorescence, we next wanted to directly assess how PKCe affects both NAD þ and NADH levels in mitochondria. In the next set of experiments, we measured the concentrations of NAD þ and NADH in mitochondria isolated from the cortex or neuronal-glial cortical cultures 48 hours after treatment. Analysis of intrinsic NADH in our previous experiment showed that PKCe regulates the NAD þ /NADH ratio in neuronal-glial cortical cultures. We now wanted to determine whether PKCe regulates the NAD þ /NADH ratio in cortical mitochondria in vivo. Mitochondria were isolated from the cortex 48 hours after intraperitoneal injection of ceRACK (0.5 mg/kg). There was no significant change in NAD þ levels. However, NADH concentrations were decreased by 65±2% (Po0.05, n ¼ 6) and the NAD þ /NADH ratio was increased by 305 ± 8% (Po0.05, n ¼ 6) ( Figure 5A ). To further delineate the pathways involved in PKCe regulation of mitochondrial NAD, we assessed NAD þ , NADH, and NAD þ /NADH ratio in neuronal-glial cortical cultures. One-hour ceRACK (100 nmol/L) exposure in cortical cultures increased mitochondrial concentrations of NAD þ by 58±4.2% (Po0.01, n ¼ 5), NADH by 16±0.5% (Po0.05, n ¼ 5), and the NAD þ /NADH ratio by 35 ± 0.7% (Po0.01, n ¼ 5) 48 hours later in comparison with control ( Figure 5B ). The significant ceRACK-mediated increases in NAD þ and NADH were blocked with the addition of the AMPK inhibitor CC (15 mmol/L). At this time it is unknown whether pathways other than Nampt may contribute to mitochondrial NAD levels. Therefore, to assess whether PKCe regulates mitochondrial NAD in a Nampt-dependent manner, isolated mitochondria from the ceRACK-treated glial-neuronal cortical cultures were also exposed to DMSO or the FK866 Nampt-specific inhibitor (25 nmol/L) for 30 minutes. Nicotinamide phosphoribosyltransferase inhibition significantly blocked PKCe-induced increases in mitochondrial concentrations of NAD þ and NADH (Po0.01, n ¼ 5) and the NAD þ /NADH ratio (Po0.01, n ¼ 5) ( Figure 5B ). Since these experiments revealed PKCe activation was sufficient to regulate mitochondrial NAD þ and NADH, we next examined whether PKCe modulates mitochondrial NAD þ /NADH, NADH, and the NAD þ /NADH ratio 48 hours after ischemic and resveratrol preconditioning in glial-neuronal cortical cultures. Ischemic preconditioning increased the concentrations of NAD þ by 62 ± 4.6% (Po0.05, n ¼ 5), NADH by 10 ± 0.6% (P ¼ 0.4, n.s., n ¼ 5), and the NAD þ /NADH ratio by 47±1.1% (Po0.05, n ¼ 5), which were blocked with the addition of the PKCe inhibitor, eV1-2 (250 nmol/L) ( Figure 6A ). Resveratrol increased the concentrations of NAD þ by 121 ± 2.9% (Po0.001, n ¼ 5), NADH by 16%±0.2% (P ¼ 0.1, n.s., n ¼ 5), and the NAD þ / NADH ratio by 93.5±0.6% (Po0.001, n ¼ 5), which was reversed with the addition of eV1-2 (100 nmol/L) ( Figure 6B ). 
DISCUSSION
Nampt and NAD have important roles in maintaining mitochondrial function against oxidative and ischemic stress. 6, 15, 17 However, the pathways involved in regulating mitochondrial-localized Nampt and NAD have not been previously investigated. The purpose of this study was to determine whether PKCe and AMPK work together to enhance mitochondrial pools of Nampt, NAD, and the mitochondrial oxidized (NAD þ ) to reduced nicotinamide adenine dinucleotide reduced (NADH) ratio in the brain. We found that PKCe activation was both sufficient and necessary to induce AMPK activity after IPC and resveratrol treatment. AMP-activated protein kinase activity was required for PKCe-mediated ischemic neuroprotection, which suggested an important functional consequence of PKCe modulation of AMPK. Indeed, we showed that PKCe activation significantly enhanced mitochondrial pools of Nampt in an AMPK-dependent manner. Furthermore, PKCe had a critical role in increasing Nampt, NAD þ , and the NAD þ /NADH ratio in mitochondria after ischemic and resveratrol preconditioning. Collectively, these findings have identified PKCe as a major regulator of the mitochondrial localization of Nampt and NAD in the brain and after ischemic and resveratrol preconditioning.
Prevention of mitochondrial dysfunction after cerebral ischemia is a major target of neuroprotective pathways. [28] [29] [30] Both PKCe and AMPK have established roles in ischemic neuroprotection and enhancing mitochondrial function. For example, our previous studies in the brain showed that PKCe mediates ischemic protection 25 and translocates to mitochondria where it regulates the mitochondrial K þ ATP channel, 26 increases mitochondrial respiration, decreases reactive oxygen species production, and inhibits cytochrome c release. 9 While PKCe has an established role in preventing brain ischemic injury, the role of AMPK in ischemic protection in the brain is less clear. For example, AMPK has been shown to promote apoptotic cell death through its interaction with p53. 31 However, AMPK also provides protection against ischemic injury 11, 15, 20 by regulating various transcription factors and coregulators (such as PGC1alpha, FOXO3a, and sirtuin 1 (SIRT1)) to induce mitochondrial biogenesis, enhance the expression of mitochondrial reactive oxygen species scavengers, and increase mitochondrial respiration. 31 Previously, both PKC activity and an upstream activator of AMPK were shown to be important in preventing N-methyl-D-aspartate-induced neurodegeneration after cerebral ischemia. 32 More recently, studies in the heart have linked AMPK to the PKC family in ischemic protection, 20 but the involvement of a specific PKC isoform has not been determined. We showed here that PKCe activates AMPK in vitro and in vivo and that PKCe requires AMPK for neuroprotection against lethal OGD. Therefore, this study represents the first report linking AMPK to PKCe for activation and ischemic neuroprotection.
AMP-activated protein kinase has previously been shown to enhance mRNA expression of Nampt, the rate-limiting enzyme in the major biosynthetic pathway for NAD production. 13, 14 Nicotinamide phosphoribosyltransferase converts nicotinamide to NMN (nicotinamide mononucleotide) which is then converted to NAD by Nmnat (NMN adenyl transferase). 13 A major factor contributing to the requirement of AMPK to provide PKCemediated ischemic neuroprotection in our experiments may lie in the ability of AMPK to regulate Nampt and NAD levels. Ischemic preconditioning and resveratrol have been shown to enhance levels of Nampt, 33, 34 which implicates Nampt as a major player in ischemic neuroprotection. Studies have shown that knockdown of Nampt increases susceptibility to cerebral ischemic infarct, while Nampt overexpression enhances neuronal survival after ischemic injury through AMPK activity. 6, 15 Despite the involvement of AMPK in enhancing Nampt mRNA expression, 14 no studies thus far have investigated the contribution of AMPK, or any other signaling pathway, in regulating mitochondrial-specific pools of Nampt.
Since we have previously shown that PKCe directly regulates mitochondrial function, 9, 26, 27 and our current experiments linked PKCe to AMPK activity, we next determined whether PKCe and AMPK were involved in modulating mitochondrial Nampt. In purified mitochondrial fractions, we found that both AMPK and PKCe activation enhanced Nampt levels that were blocked with the addition of PKCe or AMPK inhibitors, respectively. These results were particularly interesting since AMPK has been previously shown to enhance whole-cell Nampt levels, but we now showed that AMPK enhances mitochondrial-localized Nampt in a PKCe-dependent manner (Figure 7) . Similarly, both IPC and resveratrol required PKCe activity to increase mitochondriallocalized Nampt, indicating that PKCe has a crucial role in the maintenance or translocation of Nampt to the mitochondrial fraction. The fact that blockade of AMPK had no effect on the ability of IPC or resveratrol to enhance Nampt levels in the mitochondria further highlighted the importance of PKCe in regulation of mitochondrial levels. The dependence of PKCe on AMPK for increased mitochondrial Nampt may largely rest on the ability of AMPK to increase Nampt mRNA expression, whereas IPC and resveratrol may have AMPK-independent mechanisms for regulating hypoxia response elements in the Nampt promoter. 35 Since there is a mitochondrial-specific Nmnat (Nmnat-3), 36 there also remains the possibility that PKCe regulates a mitochondrialspecific isoform of Nampt. Nevertheless, PKCe regulation of mitochondrial Nampt levels provides a mechanism by which PKCe may mediate mitochondrial function and neuroprotection by enhancing mitochondrial NAD.
Nicotinamide adenine dinucleotide is an essential coenzyme used by the tricarboxylic acid cycle and electron transport chain in the maintenance of mitochondrial membrane potential and production of ATP. 1 In the brain, the mitochondria contain a large portion of the cellular pool of NAD with up to one-third or half of NAD cellular content reported to reside in the mitochondria of astrocytes or neurons, respectively. 16 Reductions in NAD during ischemic events cause DNA damage, energy depletion and lead to neurodegeneration. [4] [5] [6] 37 Nicotinamide phosphoribosyltransferase overexpression has been shown to prevent mitochondrial dysfunction and neuronal death after ischemia through its ability to produce NAD. 6, 15 Specifically enhancing mitochondriallocalized NAD after oxidative stress was shown to preserve mitochondrial membrane potential, enhanced respiration, and prevented the release of apoptosis-inducing factor in neurons. 18 Several studies in the heart and the brain have indicated that mitochondrial NAD can be maintained despite substantial depletion of cytoplasmic NAD; [16] [17] [18] [19] however, the mechanisms regulating mitochondrial NAD remain unclear. By blocking Nampt activity in isolated mitochondria, we have now revealed that PKCe regulates mitochondrial NAD in a Nampt-dependent manner. We also showed that PKCe activity after IPC and resveratrol treatment was responsible for enhanced mitochondrial NAD which further linked PKCe regulation of mitochondrial Nampt to modulation of mitochondrial NAD (Figure 7) .
By assessing both the oxidized and reduced forms of NAD we found that the PKCe-regulated increases in mitochondrial Nampt correlated with increases in the NAD þ /NADH ratio. These results mirrored previous findings where increased Nampt levels were associated with enhanced NAD þ levels. 14, 15, 19, 33 Increases in the NAD þ /NADH ratio have been linked to the activity of NAD þdependent SIRTs, 11, 14, 15, 33 which have been shown to provide protection to the mitochondria by regulating mitochondrial biogenesis and bioenergetics. 38 The mitochondrial SIRTs, SIRT3 and SIRT4, have been shown to have integral roles in mitochondrial-Nampt-dependent protection against genotoxic stress. 19 In a recent study, we showed that PKCe induces increases in SIRT1 mitochondrial levels. 27 The results from our current study indicate that PKCe may also regulate mitochondrial SIRT activity by increasing the NAD þ /NADH ratio in mitochondria (Figure 7) . Another set of enzymes dependent on NAD þ are poly-ADP-ribose polymerases (PARPs), DNA-repair enzymes activated during cellular stress. During ischemia, overactivation of PARPs mediates NAD þ depletion and apoptotic signaling. 3, 4 Protein kinase C epsilon-mediated increases in mitochondrial NAD þ availability may help to maintain pools of NAD þ during activity of mitochondrial-localized PARPs (Figure 7) , thereby maintaining mitochondrial DNA integrity and preventing cell death. 18, 39 The protective role of Nampt against neurodegenerative damage has recently become the focus of intense investigation. 40 In this study, we have expanded the focus to understand how mitochondrial pools of Nampt, NAD, and the NAD þ /NADH ratio are regulated by a PKCe-AMPK pathway during IPC and resveratrol treatment. The role of PKCe and AMPK crosstalk in mitochondrial protection should be further investigated since AMPK may also confer protection via pathways previously thought as PKCedependent-only and vice versa. Our findings also provide the initial steps in answering a previously unknown question of how mitochondria maintain NAD levels. Preservation of mitochondrial NAD during ischemic or oxidative stress may enhance neuronal viability by maintaining the activity of the electron transport chain, enhancing SIRT activity, and preventing PARP-mediated NAD þ depletion. Future research should focus on determining how Nampt is imported into the mitochondria and whether a mitochondrial Nampt isoform exists. Elucidating these gaps may provide enhanced mechanisms for protecting mitochondria against ischemic and oxidative injury.
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